Anti-tumor NAMPT inhibitor, KPT-9274, mediates gender-dependent murine anemia and nephrotoxicity by regulating SIRT3-mediated SOD deacetylation

KPT-9274 is a phase 1 first-in-class dual PAK4/NAMPT inhibitor for solid tumor and non-Hodgkin’s lymphoma. It demonstrates pre-clinical efficacy toward a broad spectrum of acute myeloid leukemia (AML) subtypes by inhibiting NAMPT-dependent NAD(+) production. NAMPT is the rate-limiting enzyme in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitchell, Shaneice, Zhang, Pu, Cannon, Matthew, Beaver, Larry, Lehman, Amy, Harrington, Bonnie, Sampath, Deepa, Byrd, John C., Lapalombella, Rosa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8243474/
https://www.ncbi.nlm.nih.gov/pubmed/34187548
http://dx.doi.org/10.1186/s13045-021-01107-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8243474/
https://www.ncbi.nlm.nih.gov/pubmed/34187548
http://dx.doi.org/10.1186/s13045-021-01107-0

Ejemplares similares